Sector News

Bristol-Myers expands I/O hub

April 15, 2016
Life sciences

Bristol-Myers Squibb is once again growing its footprint in the fast-growing immuno-oncology R&D world.

The biopharma company inked a lease on the third and final facility BioMed Realty owns at Woodside Technology Park in Redwood City, CA, opening the door to an expansion of its biologics discovery team, set to grow from the 250 now employed at the hub to as many as 400 with the add-on.

Bristol-Myers’ deal nabbed the last 62,000 square feet of space at the park, which brings its total in the Bay Area Peninsula biotech area to 256,000 square feet–a clean sweep of the campus it first moved into close to three years ago. A spokesperson for the company tells FierceBiotech that the expansion could add up to 150 staffers on site.

The campus is devoted primarily to the company’s big R&D efforts in immuno-oncology, a field that Bristol-Myers now dominates with its pioneering drug Opdivo.

The leases for Bristol-Myers started back in 2013, when the company inked a contract for the first big building on the site. The second facility was taken in 2014.

During the past three years Bristol-Myers has been steadily upping its game in I/O. Opdivo–a pioneering drug designed to unleash an immune system assault on cancer cells–has been quickly penetrating the vast oncology market, nabbing label expansions and competing head-to-head with Merck’s Keytruda.

“The expansion of our facilities in Redwood City is evidence of the value that Bristol-Myers Squibb sees in the Bay Area scientific community and our relationship with BioMed Realty,” said Nils Lonberg, head of oncology biology discovery at Bristol-Myers Squibb.

By John Carroll

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.